PD-1/PD-L1免疫检查点抑制剂抗肿瘤治疗现状及其疗效预测标志物的研究进展

被引：12

作者：

姜玉勃 ^{[1
,2
]}

刘昱辰 ^{[2
]}

黄勇 ^{[2
]}

徐建明 ^{[1
]}

机构：

[1] 军事医学科学院附属医院消化肿瘤科

[2] 解放军第医院特诊科

来源：

癌症进展 | 2018年 / 16卷 / 11期

关键词：

免疫检查点; PD-1; PD-L1; 肿瘤; 疗效预测; 生物标志物;

D O I：

暂无

中图分类号：

R730.51 [免疫疗法];

学科分类号：

100214 ;

摘要：

肿瘤免疫治疗是近年肿瘤治疗领域的研究热点,尤其是免疫检查点抑制剂的成功开发与应用,更是将肿瘤免疫治疗带入了一个新时代。与化疗、放疗、靶向治疗等常规治疗方法直接作用于肿瘤细胞不同,免疫检查点抑制剂是通过阻断肿瘤微环境中免疫检查点通路,激发肿瘤特异性T细胞功能,从而改善内源性抗肿瘤免疫,达到抗肿瘤效果。现在已有多种程序性死亡受体1(PD-1)/程序性死亡受体配体1(PD-L1)单抗获得美国食品药品监督管理局(FDA)批准用于临床抗肿瘤治疗;但PD-1/PD-L1单抗在临床应用中也面临诸多挑战,如疗效预测生物标志物的选择和联合治疗等。本文对PD-1/PD-L1通路的免疫学机制、PD-1/PD-L1通路与肿瘤免疫逃逸以及目前经FDA批准的PD-1/PD-L1单抗研究现状作一综述,并讨论了目前比较热门的预测PD-1/PD-L1单抗疗效的生物标志物的研究进展。

引用

页码：1319 / 1327

页数：9

共 28 条

[1]

系统筛查微卫星不稳定性结直肠癌的意义和策略[J]. 石雪迎,郑杰.中华病理学杂志. 2015 (01)

[2]

肿瘤个体化与靶向免疫治疗学[M]. 科学出版社 , 刘宝瑞, 2017

[3]

免疫学前沿进展[M]. 人民卫生出版社 , 曹雪涛, 2017

[4]

Cancer immunotherapies targeting the PD-1 signaling pathway[J] . Yoshiko Iwai,Junzo Hamanishi,Kenji Chamoto,Tasuku Honjo.Journal of Biomedical Science . 2017 (1)

[5]

FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma[J] . Amy Barone,Maitreyee Hazarika,Marc R. Theoret,Pallavi Mishra-Kalyani,Huanyu Chen,Kun He,Rajeshwari Sridhara,Sriram Subramaniam,Elimika Pfuma,Yaning Wang,Hongshan Li,Hong Zhao,Jeanne Fourie Zirkelbach,Patricia Keegan,Richard Pazdur.Clinical Cancer Research . 2017 (19)

[6]

Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy[J] . Khagi Yulian,Goodman Aaron M,Daniels Gregory A,Patel Sandip P,Sacco Assuntina G,Randall James M,Bazhenova Lyudmila A,Kurzrock Razelle.Clinical cancer research : an official journal of the American Association for Cancer Research . 2017 (19)

[7] Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 [J].

Champiat, Stephane ;

Dercle, Laurent ;

Ammari, Samy ;

Massard, Christophe ;

Hollebecque, Antoine ;

Postel-Vinay, Sophie ;

Chaput, Nathalie ;

Eggermont, Alexander ;

Marabelle, Aurelien ;

Soria, Jean-Charles ;

Ferte, Charles .

CLINICAL CANCER RESEARCH, 2017, 23 (08) :1920-1928

[8]

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial[J] . Padmanee Sharma,Margitta Retz,Arlene Siefker-Radtke,Ari Baron,Andrea Necchi,Jens Bedke,Elizabeth R Plimack,Daniel Vaena,Marc-Oliver Grimm,Sergio Bracarda,José ángel Arranz,Sumanta Pal,Chikara Ohyama,Abdel Saci,Xiaotao Qu,Alexandre Lambert,Suba Krishnan,Alex Azrilevich,Matthew D Galsky.The Lancet Oncology . 2017 (3)

[9]

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J] . Achim Rittmeyer,Fabrice Barlesi,Daniel Waterkamp,Keunchil Park,Fortunato Ciardiello,Joachim von Pawel,Shirish M Gadgeel,Toyoaki Hida,Dariusz M Kowalski,Manuel Cobo Dols,Diego L Cortinovis,Joseph Leach,Jonathan Polikoff,Carlos Barrios,Fairooz Kabbinavar,Osvaldo Arén Frontera,Filippo De Marinis,Hande Turna,Jong-Seok Lee,Marcus Balli

[10]

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study[J] . Matthew D Hellmann,Naiyer A Rizvi,Jonathan W Goldman,Scott N Gettinger,Hossein Borghaei,Julie R Brahmer,Neal E Ready,David E Gerber,Laura Q Chow,Rosalyn A Juergens,Frances A Shepherd,Scott A Laurie,William J Geese,Shruti Agrawal,Tina C Young,Xuemei Li,Scott J Antonia.The Lancet Oncology . 2017 (1)

← 1 2 3 →